European Companies Search Engine
EU funding (€4,044,794): Enhancing CHO by Mammalian Systems Biotechnology (eCHO systems) Hor 1 Jan 2015 EU Research and Innovation programme "Horizon"
Overview
Text
Enhancing CHO by Mammalian Systems Biotechnology (eCHO systems)
Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Current CHO production platforms dates to 1980 and are based primarily on media and process optimisation with little consideration to the optimization of the cellular machinery. Fortunately, with the recent sequencing of the CHO genome, an opportunity has opened to significantly advance the CHO platform. The benefit will be advanced production flexibility and a lower production cost. This ITN graduate training programme - eCHO Systems - will blend conventional molecular, cellular, and synthetic biology with genome scale systems biology training in ‘omics data acquisition, biological network modeling, and genome engineering in three interdisciplinary topics: 1) Acquisition of large scale ‘omics data sets and their incorporation into genome-scale mathematical models 2) Development of genome engineering tools, enabling synthetic biology 3) Application of systems and synthetic biology and genome engineering to improve performance of CHO producers The training projects are supported by 15 industrial participants, which will participate in the research and test the results. ESR training will include intense courses focused on computational systems biology, cell biology, business and entrepreneurship. The three universities bring unique complementary skills in systems and synthetic biology, ‘omics technologies, cytometry, and molecular cell biology which will provide depth and breadth to this training. The eCHO Systems will produce four major outputs: General knowledge to improve the productivity, quality, and efficiency of CHO platform cell lines, new systems models for CHO cells, new CHO cell line chassises generated through synthetic biology approaches, high quality education at the graduate level, and a cadre of interdisciplinary graduates poised to transform biopharmaceutical biotechnology.
Funded Companies:
| Company name | Funding amount |
| Bioneer A/S | ? |
| Acib GmbH | €1,017,019 |
| Danmarks Tekniske Universitet | €1,160,328 |
| Dublin City University | €797,024 |
| Rentschler Biotechnologie GmbH | €0.00 |
| UCB Pharma SA | €250,560 |
| University of Kent | €819,864 |
Source: https://cordis.europa.eu/project/id/642663
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Bioneer A/S, Hørsholm, Denmark.